Terms: = Thyroid cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2
4 results:
1. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract] [Full Text] [Related]
2. Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics.
Zhang Y; Garofano F; Wu X; Schmid M; Krawitz P; Essler M; Schmidt-Wolf IGH
Invest New Drugs; 2020 Dec; 38(6):1717-1729. PubMed ID: 32500465
[TBL] [Abstract] [Full Text] [Related]
3. The relationship between iodine intake and the risk of thyroid cancer: A meta-analysis.
Cao LZ; Peng XD; Xie JP; Yang FH; Wen HL; Li S
Medicine (Baltimore); 2017 May; 96(20):e6734. PubMed ID: 28514290
[TBL] [Abstract] [Full Text] [Related]
4. Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO.
Rebuffat SA; Morin M; Nguyen B; Castex F; Robert B; Péraldi-Roux S
Br J Cancer; 2010 Mar; 102(5):852-61. PubMed ID: 20145622
[TBL] [Abstract] [Full Text] [Related]
